Search Within

Maria Lia Palomba

Formats
  1. Meeting Abstract (289)
  2. Journal Article (131)
  3. Research Letter (10)
  4. Review (8)
  5. Correspondence (4)
  6. Editorial (3)
  7. Book Section (1)
  8. Conference Paper (1)
  9. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (448)
  2. Department of Medicine (448)
  3. Hematologic Malignancies, Division of (448)
  4. Lymphoma (448)
  5. Hematology-Oncology Fellows (228)
  6. Survivorship Research (209)

More Groups

People
  1. Andrew Zelenetz (143)
  2. Ariela Noy (132)
  3. Paul Hamlin (126)
  4. Gilles Salles (114)
  5. Steven Horwitz (112)
  6. Gunjan Shah (111)

More People

Years
  1. 2025 (19)
  2. 2024 (58)
  3. 2023 (69)
  4. 2022 (39)
  5. 2021 (41)
  6. 2020 (43)

More Years

Publications
  1. Blood (187)
  2. Journal of Clinical Oncology (37)
  3. Hematological Oncology (30)
  4. Blood Advances (19)
  5. Blood Cancer Journal (15)
  6. British Journal of Haematology (14)

More Publications

Publishers
  1. American Society of Hematology (207)
  2. Elsevier Inc. (45)
  3. American Society of Clinical Oncology (38)
  4. Nature Publishing Group (33)
  5. Wiley Blackwell (31)
  6. John Wiley & Sons (14)

More Publishers

Results (448)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia
    Journal Article

    Xu, L.; Tsakmaklis, N.; Yang, G.; Chen, J. G.; Liu, X.; Demos, M.; Kofides, A.; Patterson, C. J.; Meid, K.; Gustine, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Utility of MYD88 in the differential diagnosis and choice of second-line therapy in a case of nonsecretory lymphoplasmacytic lymphoma versus free light chain waldenstrom's macroglobulinemia
    Journal Article

    Kazmierski, D.; Palomba, M. L.; Barsigian, C.
    Case Reports in Hematology (2017)

    Fulltext@MSK | Save
  • Molecular basis of ibrutinib resistance in Waldenstrom's macroglobulinemia
    Meeting Abstract

    Xu, L.; Tsakmaklis, N.; Yang, G.; Chen, J. G.; Liu, X.; Chen, J.; Demos, M.; Patterson, C. J.; Dubeau, T.; Meid, K.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Mutated MYD88 zygosity and CXCR4 mutation status are important determinants of ibrutinib response and progression free survival in Waldenstrom's macroglobulinemia
    Meeting Abstract

    Treon, S. P.; Tsakmaklis, N.; Meid, K.; Yang, G.; Chen, J. J. G.; Liu, X.; Chen, J.; Demos, M.; Patterson, C. J.; Dubeau, T.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Ibrutinib combined with rituximab in treatment-naive patients with follicular lymphoma: Arm 1 + Arm 2 results from a multicenter, open-label phase 2 study
    Meeting Abstract

    Fowler, N.; Nastoupil, L.; de Vos, S.; Knapp, M.; Flinn, I. W.; Chen, R. W.; Advani, R. H.; Bhatia, S.; Martin, P.; Mena, R.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save